We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current BVX market cap is 9.49M. The company's latest EPS is GBP -0.0303 and P/E is -3.80.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Revenue | 0 | 0 | 31k | 0 | 0 |
| Operating Income | -480k | -526k | -509k | -1.89M | -2.98M |
| Net Income | -378k | -409k | -425k | -2.34M | -2.5M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Assets | 348k | 266k | 1.07M | 6.88M | 4.54M |
| Total Liabilities | 38k | 86k | 1M | 554k | 579k |
| Total Equity | 310k | 180k | 67k | 6.33M | 3.96M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Operating | -484k | -357k | -166k | -1.79M | -2.4M |
| Investing | N/A | N/A | -63k | -46k | -379k |
| Financing | 553k | 275k | 962k | 7.03M | N/A |
| Market Cap | 9.49M |
| Price to Earnings Ratio | -3.80 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 2.89 |
| Price to Book Ratio | 2.4 |
| Dividend Yield | - |
| Shares Outstanding | 82.53M |
| Average Volume (1 week) | 69.73k |
| Average Volume (1 Month) | 59.97k |
| 52 Week Change | -20.69% |
| 52 Week High | 15.90 |
| 52 Week Low | 10.45 |
| Spread (Intraday) | 1 (8.33%) |
| Company Name | Bivictrix Therapeutics Plc |
| Address |
c/o slater heelis limited manchester M3 2ER |
| Website | https://www.bivictrix.com |
| Industry | coml physical, biologcl resh (8731) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
